Vitamin D supplementation has no effect on conventional cardiovascular risk factors: A parallel-group, double-blind, placebo-controlled RCT

Adrian D. Wood, Karen R. Secombes, Frank Thies, Lorna Aucott, Alison J. Black, Alexandra Mavroeidi, William G. Simpson, William D. Fraser, David M. Reid, Helen M. Macdonald

Research output: Contribution to journalArticlepeer-review

160 Citations (Scopus)


Context: Observational studies show an association between low vitamin D status assessed by circulating 25-hydroxyvitamin D and cardiovascular events and mortality. Data from randomized controlled trials are limited. Objective: The aim of this study was to test whether daily doses of vitamin D at 400 or 1000 IU/d for 1 yr affected conventional markers of cardiovascular disease (CVD) risk. Design: We conducted a parallel-group, double-blind, placebo-controlled randomized controlled trial. Randomization was computer generated. Participants and study investigators were blinded to intervention groupings throughout the trial. Setting: The study was conducted at the Clinical Research Facility, University of Aberdeen, United Kingdom. Participants: Atotal of 305 healthy postmenopausal women aged 60-70 yr were recruited for the study. Intervention: Each woman received a daily capsule of 400 or 1000 IU vitamin D3 or placebo randomly allocated. Main Outcome Measures: Primary outcomes were serum lipid profile [total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B ], insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, soluble intracellular adhesion molecule-1), and blood pressure. Results: Atotal of 265 (87%) participants completed all study visits. Small differences between groups for serum apolipoprotein B change [repeated measures ANOVA, P = 0.04; mean (SD), -1.0 (10.0) mg/dl (400 IU); -1.0 (10.0) mg/dl (1000 IU); and +0.02 (10.0) mg/dl (placebo)] were not considered clinically significant. Other systemic markers for CVD risk remained unchanged. There was significant seasonal variation in systolic and diastolic blood pressure independent of vitamin D dose (P
Original languageEnglish
Pages (from-to)3557-3567
Number of pages11
JournalThe Journal of Clinical Endocrinology and Metabolism
Issue number10
Publication statusPublished - 1 Oct 2012


  • Aged
  • Biological Markers
  • Cardiovascular Diseases
  • Cholecalciferol
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Placebos
  • Postmenopause
  • Risk Factors
  • Risk Reduction Behavior
  • Vitamins

Cite this